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We report a rare case of primary vulval rhabdoid tumor in an adult. The diagnosis was conﬁrmed using the recently emerging
INI1/BAF47 immunostain. We also demonstrate the expression of ER and PR hormonal receptors by the tumor cells.
1.Introduction
Extrarenal malignant rhabdoid tumors (EMRTs) are rare
and highly aggressive neoplasms. Although they are known
to occur during infancy and childhood, their occurrence
in adults is reported. EMRTs were described in various
anatomical sites, and the use of INI1 immunostain has
recently emerged as an important adjunct for identifying
these tumors. An extensive online search of the literature
revealed very few reported cases of EMRT of the vulva [1–
10]. We hereby report another case and the ﬁrst in which the
INI1, ER, and PR immunostains were utilized.
2.CaseDescription
A 25-year-old Saudi female, who is medically free, presented
to our emergency department complaining of a mass in
the mons pubis. The mass was occasionally tender and
had rapidly increased in size in two-week duration. No
other complains or masses at other sites were reported. On
clinical examination, an ill-deﬁned soft mass was identiﬁed
in the mons pubis, extending to the left inguinal area with
a hyperemic overlying skin. Laboratory tests were within
normal limits except for a mild leukocytosis. The clinical
impression was of an abscess, and the patient was scheduled
for surgery. A local excision of the mass was done, and the
specimen was sent to the histopathology department. The
patient was discharged on the next day of surgery.
2.1. Gross Findings. Grossly, the specimen consisted of
two irregular pieces of soft tissue. Both masses were
partially encapsulated and measured 6×5×2cm and
6.5×6×2.5cm, respectively. The outer surface of both
masses was irregular. Serial slicing of the masses revealed
a heterogeneous cut surface with pale white and dark tan
areas. Random sections from both masses were taken for
histopathological examination.
2.2.MicroscopicFindings. H&Eslidesshowedapoorlydiﬀer-
entiated neoplasm. The tumor consisted exclusively of cells
retaining the classical “rhabdoid” morphology (Figure 1).
The cells were discohesive with distinct cell borders, and
they were arranged in solid sheets. The amount of cytoplasm
varied between scant to abundant. The cytoplasm had a
prominent eosinophilic quality, and intracytoplasmic glassy
eosinophilic inclusions were seen within the majority of
the cells. The nuclei were vesicular, eccentric, and highly
pleomorphic with prominent nucleoli. Numerous mitoses
were seen (45mitoses/10HPF). Occasional multinucleated
tumor giant cells were present. There were neither areas of
necrosis nor lymphovascular invasion.2 Case Reports in Medicine
Figure 1: The classical “rhabdoid” morphology of the tumor
comprising the cytoplasmic hyaline globules and the eccentric
nucleus. Mitotic ﬁgures are also seen (H&E stain, magniﬁcation
power×400).
2.3. Immunohistochemical Findings. An extended panel of
antibodies was performed on Ventana using the iVIEW DAB
detection kit and showed focal cytoplasmic immunoreactiv-
ity to vimentin (mouse monoclonal, 1:60; Dako) with the
characteristic globular cytoplasmic conﬁguration indenting
the nucleus. The cytoplasm of tumor cells also coexpressed
cytokeratin cocktail (mouse monoclonal, AE1/AE3, 1:100;
Dako), CK 8 (mouse monoclonal, ready to use; Dako), and
CK 19 (mouse monoclonal, 1:40; Dako). The tumor cells,
in comparison to the endothelial lining of the capillaries,
showed loss of INI1 (mouse monoclonal, BAF 47, ready to
use; BD Transduction Laboratories, USA) nuclear staining
(Figure 2). Anti-Ki-67 (mouse monoclonal, 1:50; Dako)
showed a high proliferation index reaching up to 80% of
tumor cells. Tumor cells have showed nuclear positivity to
ER (mouse monoclonal, 1:20; Dako) (weak to moderate
in 90%) (Figure 3) and have also showed nuclear positivity
to PR (mouse monoclonal, 1:100; Dako) (strong in 20%).
All other immunohistochemical (IHC) stains were negative
including CD34, EMA, CD99, CD117, CD45, CD30, CD138,
bcl-6, bcl-2, CK7, CK20, GCDFP, muscular diﬀerentia-
tion markers (Desmin, SMA, Myoglobin), neuroendocrine
markers (Synaptophysin, Chromogranin A, CD56), and
melanoma markers (S100, HMB-45).
A diagnosis of malignant rhabdoid tumor of the
vulva was established. The patient was recalled once the
histopathology report was signed out. A computed tomogra-
phy scan (CT) of the head, chest, abdomen, and pelvis was
performed and revealed no other tumor masses. Unfortu-
nately, the patient failed to show for followup.
3. Discussion
W er e p o r tac a s eo fE M R To ft h ev u l v ai na2 5 - y e a r -
old female. The age of the patient, the site of the tumor,
the clinical presentation, and the microscopic ﬁndings in
our case were compatible with the 12 previously reported
cases (Table 1)[ 1–10]. The IHC proﬁle varied between
cases, and the only universal ﬁnding was immunoreactivity
to vimentin. Recently, INI1 immunostain has emerged as
Figure 2: INI1/BAF47 immunostain showing loss of nuclear
staining in the rhabdoid cells in comparison to the positive nuclei
of the endothelial cells (INI1/BAF47 immunohistochemical stain,
magniﬁcation power×200).
Figure 3: Weak-to-moderate ER nuclear expression of the tumor
cells (ER immunohistochemical stain, magniﬁcation power×400).
an adjunct for identifying rhabdoid tumors and atypical
rhabdoid/teratoid tumors (AT/RTs). INI1, encoded by the
INI1/hSNF5/SMARCB1/BAF47 locus at 22q11.2, is a mem-
beroftheSWI/SNFchromatin-remodelingcomplex,anditis
normally expressed in all tissues [11, 12]. The biallelic inac-
tivation of this gene is characteristic to rhabdoid tumors of
the kidney, EMRTs, and AT/RTs [11, 12]. We have conﬁrmed
our diagnosis using the INI1/BAF47 antibody which showed
universal loss of nuclear INI1 protein expression in all tumor
cells. We have also studied the hormonal status of this tumor
and found it to express both ER and PR receptors. This
ﬁnding is compatible with its primary location in the vulva
andhasbeenpreviouslyreportedinothervulvaltumors[13].
Malignant rhabdoid tumor was originally described in
the kidney as a variant of Wilms’ tumor. In 1982, the ﬁrst
extrarenal malignant rhabdoid tumor was reported, and
since then this entity was recognized at various anatomical
sites including soft tissues, liver, prostate, thymus, skin,
pelvis, heart, and central nervous system [14, 15]. These
tumors have a predilection to the pediatric age group
though cases in adults were repeatedly recognized. The
common microscopic feature is the “rhabdoid” cell of whichCase Reports in Medicine 3
Table 1: Characteristics of the previously reported cases of EMRT of the vulva [1–10].
Author, year Age at diagnosis
(years) Site Primary treatment Reported survival
(months)
19 R LMJ 38 (alive)
Perrone et al., 1989§ [1] 30 R LMJ Surgery 8 (dead)
31 L vulva 138 (dead)
Matias et al., 1990 [2] 49 L LMJ Surgery + chemotherapy 9 (dead)
Lupi et al., 1996 [3] 39 L LMJ Surgery + chemotherapy + radiation 4 (dead)
Igarashi et al., 1998 [4] 39 L LMJ Surgery + chemotherapy 8 (alive)
Sert et al., 1999 [5] 44 R LMJ Surgery + chemotherapy + radiation 8 (dead)
Brand and Covert 2001 [6] 40 Mons pubis Surgery + chemotherapy + radiation 61 (alive)
Haidopoulos et al., 2002 [7] — Clitoris — —
Tzilinis et al., 2002 [8] 63 L LMJ Surgery + radiation 30 (alive)
Argenta et al., 2007C [9] 35 R vulva Surgery + radiation 40 (alive)
Narendra et al., 2010 [10] 50 R LMJ and mons pubis Surgery + radiation 30 (alive)
Current case 25 Mons Pubis, extending
to L inguinal area Surgery Lost followup
R: right. L: left. §3 cases were reported. No full text is available in PubMed. CThe diagnosis given was EMRT/proximal epithelioid sarcoma.
the entire tumor is composed. These tumors usually coex-
press vimentin and cytokeratin, and they do not retain the
nuclear expression of INI1 protein. The prognosis of ERMT
is generally poor, and their course tends to be aggressive.
Although surgery is the ﬁrst line of management, there
is no consensus that exists regarding adjuvant therapies.
Chemotherapy and radiotherapy did not show to be eﬀective
in controlling the recurrent or metastatic disease in all
reported cases [1–15].
I ns u m m a r y ,v u l v a lE M R T sa r er a r ea n da g g r e s s i v e
neoplasms and should be considered in the diﬀerential
diagnosis of any high-grade undiﬀerentiated tumor at this
site. Given that IHC is much more widely available than
molecular tests, INI1/BAF47 immunostain represents the
most useful, up to date ancillary technique to conﬁrm
this diagnosis. Although these tumors express ER and PR
receptors,theirresponsetoantihormonaltherapyisaremote
possibility [13].
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